Mostrar el registro sencillo del ítem

dc.contributor.authorRiquelme Gallego, Blanca 
dc.contributor.authorSánchez-Delgado, Guillermo
dc.contributor.authorGonzález Salvatierra, Sheila
dc.contributor.authorGarcía Recio, Enrique 
dc.contributor.authorMuñoz Torres, Manuel Eduardo 
dc.date.accessioned2020-09-23T11:14:04Z
dc.date.available2020-09-23T11:14:04Z
dc.date.issued2020-02-04
dc.identifier.citationRiquelme-Gallego, B., García-Molina, L., Cano-Ibáñez, N., Sánchez-Delgado, G., Andújar-Vera, F., García-Fontana, C., ... & Muñoz-Torres, M. (2020). Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients. Scientific reports, 10(1), 1-10. [https://doi.org/10.1038/s41598-020-58760-7]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/63517
dc.description.abstractUndercarboxylated osteocalcin (ucOC) could be a biomarker of glucose disturbances and cardiovascular risk. Our study aimed to determine the association between serum levels of ucOC and cardiovascular risk in metabolic syndrome (MetS) patients and to analyse its potential role as estimator of type 2 diabetes (T2D) risk in this population. This cross-sectional study included 235 patients with MetS, 53.2% women, aged 55–75 years. Circulating ucOC levels were measured by ELISA. Cardiovascular risk was determined as Z-score of the diagnostic criteria for MetS (CV-ZS). Linear regression model was performed to analyse the association between circulating ucOC and CV-ZS. A receiver operating curve (ROC) was performed to analyse the usefulness of ucOC as T2D risk estimator. Patients above the CV-ZS median showed signifcant lower ucOC levels. We found an inverse association between ucOC levels and CV-ZS in MetS patients without T2D. Patients with ucOC levels below the 25th percentile showed worse cardiometabolic profle and higher cardiovascular and T2D risk. The area under the curve performed better when ucOC levels were included along with the classic T2D risk factors. The measurement of circulating ucOC could be a useful tool to identify increased cardiovascular and T2D risk in MetS patients without T2D.es_ES
dc.description.sponsorshipJunta de Andalucia PI-0207-2016es_ES
dc.description.sponsorshipEuropean Union (EU) PI18-00803 PI18-01235es_ES
dc.language.isoenges_ES
dc.publisherNature Researches_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.titleCirculating Undercarboxylated Osteocalcin as Estimator of Cardiovascular and Type 2 Diabetes Risk in Metabolic Syndrome Patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1038/s41598-020-58760-7


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España